Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Exact Sciences Corporation - Common Stock (NQ:EXAS)

52.21 -1.46 (-2.72%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Exact Sciences Corporation - Common Stock

< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
18 19 Next >
Why Exact Sciences Stock Slumped Wednesday
The biotech's Q2 numbers were impressive overall, but Wall Street apparently wasn't satisfied. 
Via The Motley Fool
Exact Sciences Q2 Earnings Surpass Expectation, But Analyst Says Stock Has Limited Growth
Exact Sciences Corp (NASDAQ: EXAS) reported Q2 revenue of $622 million, an increase of 19%, and $617 million of core revenue, an increase of 24%, beating the  
Via Benzinga
Why Exact Sciences Shares Are Trading Lower By Over 9%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Gainers WaveDancer, Inc. (NASDAQ: WAVD) shares climbed 86% to $0.5505. Tellenger, a subsidiary of Wavedancer, Inc., won a seven-year U.S. government contract. 
Via Benzinga
Exact Sciences (EXAS) Q2 2023 Earnings Call Transcript
EXAS earnings call for the period ending June 30, 2023. 
Via The Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For August 2, 2023
Via Benzinga
Exact Sciences, A Cathie Wood Darling, Just Reported A Sixth Big Sales Quarter
The company is a leader in using diagnostics to screen for early cancer cases. 
Via Investor's Business Daily
Earnings Preview For Exact Sciences
Via Benzinga
Accenture, Hewlett Packard Enterprise And 2 Other Stocks Insiders Are Selling
The Nasdaq 100 closed higher on Friday. Investors, meanwhile, focused on some notable insider trades. 
Via Benzinga
2 Revolutionary Stocks to Buy and Hold for 10 Years
Breaking new ground can be highly lucrative. 
Via The Motley Fool
Expert Ratings for Exact Sciences
Via Benzinga
Analyst Ratings for Exact Sciences
Via Benzinga
Canaccord Genuity Maintains Buy Rating for Exact Sciences: Here's What You Need To Know
Via Benzinga
Cathie Wood's Ark Invest Continues To Sell Shares Of Warren Buffett-Backed BYD — Coinbase Holdings Trimmed As Well
Via Benzinga
Cathie Wood's Ark Invest Makes Major Moves In This Warren Buffett-Backed EV Company, Moderna
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
3 Growth Stocks Every Investor Should Know About Now
While a countless number of ideas flood the capital markets, these must-know growth stocks should be on your radar. 
Via InvestorPlace
2 Cathie Wood Growth Stocks That Could Make You Richer
These two biotechs could be winning plays for aggressive investors. 
Via The Motley Fool
Amicus Therapeutics Stock Sees Improving Market Leadership; Earns 81 RS Rating
On Monday, Amicus Therapeutics stock got an upgrade to its Relative Strength (RS) Rating, to 81, up from 74 a day earlier. 
Via Investor's Business Daily
ARKK: The Pros and Cons Of Buying Into Cathie's Best-Known ETF
If you're a believer in the progress of science and technology and feel strongly that our best days are still ahead, then a slice of ARKK could be tempting. 
Via MarketBeat
Topics ETFs Economy
ETF Returns: Mid-Cap Winners And Losers
We performed a screening of mid-cap ETFs - defined as having Assets Under Management (AUM) between $2 billion and $10 billion - to determine what funds had the largest positive and negative returns on... 
Via Benzinga
Analysts Think This Soaring Cathie Wood Stock Has Peaked. Are They Right?
Is it a matter of time before Exact Sciences stock starts giving back some of its impressive gains this year? 
Via The Motley Fool
Cathie Wood's Ark Outshines S&P 500, Nasdaq In H1: Here Are The Major Trades It Made
Via Benzinga
This Big Cathie Wood Stock Is Outperforming Even Tesla
DraftKings is the strongest performer among Ark Invest's major holdings. 
Via Investor's Business Daily
Cologuard's Improved Performance to Accelerate Growth, Analyst Raises Expectations
Tuesday, Exact Sciences Corp (NASDAQ: EXAS) announced topline results from the pivotal BLUE-C study, showing that next-generation  
Via Benzinga
Stock Market Pulls Back After Several Weeks Of Gains: Weekly Review
But the major indexes and leading stocks generally showed healthy action. 
Via Investor's Business Daily
Analysts Bullish On Exact Sciences' Advanced Cancer Screening
Exact Sciences sees a bump in stock price amid rising revenue and study results that show advancements to its flagship Cologuard colorectal screening product. 
Via MarketBeat
Exact Sciences Set To Dominate Emerging Precision Oncology Market: Analyst Applauds $18B Potential Market
Benchmark analyst Bruce D. 
Via Benzinga
2 Stocks to Invest $500 In and Hold For 10 Years
Both companies have outperformed the market over the past year. 
Via The Motley Fool
Exact Sciences Stock Is Trading Higher: What's Going On?
Exact Sciences Corp (NASDAQ: EXAS) shares are trading higher Wednesday after the cancer screening and diagnostics company said its Cologuard test demonstrated 94% sensitivity for  
Via Benzinga
Why Exact Sciences Stock Is Moving Higher After Hours
Exact Sciences Corp (NASDAQ: EXAS) shares are rising in extended trading Tuesday after the cancer screening and diagnostics company said its Cologuard test demonstrated 94% sensitivity for  
Via Benzinga
< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
18 19 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.